These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 11324823

  • 1. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.
    Rusconi S, De Pasquale MP, Mainini F, Bulgheroni E, Kurtagic S, Gori A, Violin M, Zanchetta N, Moroni M, Balotta C, Galli M.
    Antivir Ther; 1996 Dec; 1(4):211-9. PubMed ID: 11324823
    [Abstract] [Full Text] [Related]

  • 2. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
    Relimpio F, Rey C, Pineda JA, Leal M, Caruz A, Sánchez-Quijano A, Lissen E.
    Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Selection of zidovudine resistance mutations and escape of human immunodeficiency virus type 1 from antiretroviral pressure in stavudine-treated pediatric patients.
    Maxeiner HG, Keulen W, Schuurman R, Bijen M, de Graaf L, van Wijk A, Back N, Kline MW, Boucher CA, Nijhuis M.
    J Infect Dis; 2002 Apr 15; 185(8):1070-6. PubMed ID: 11930317
    [Abstract] [Full Text] [Related]

  • 5. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
    Ruiz L, Romeu J, Ibáñez A, Cabrera C, Puig T, Morales MA, Sirera G, Clotet B.
    Antivir Ther; 1996 Dec 15; 1(4):220-4. PubMed ID: 11324824
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K.
    Verh K Acad Geneeskd Belg; 2001 Dec 15; 63(5):447-73. PubMed ID: 11813503
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
    Nicastri E, Sarmati L, d'Ettorre G, Palmisano L, Parisi SG, Uccella I, Rianda A, Concia E, Vullo V, Vella S, Andreoni M.
    J Med Virol; 2003 Jan 15; 69(1):1-6. PubMed ID: 12436471
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load.
    Rubio A, Gómez-Cano M, Puig T, Leal M, Pérez-Olmeda M, Ruiz L, Clotet B, Rey C, Zamora L, Xaus N, Soriano V.
    Antivir Ther; 1999 Jan 15; 4(1):45-9. PubMed ID: 10682128
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Loss of zidovudine related mutations in the reverse transscriptase gene of HIV after switching therapy.
    Falkensammer B, El Attal R, Müllauer B, Sarcletti M, Parson W, Dierich MP, Stoiber H.
    Eur J Med Res; 2002 Sep 30; 7(9):379-86. PubMed ID: 12435615
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.